title: The effect of controlled release of PDGF-BB from heparin-conjugated electrospun PCL/gelatin scaffolds on cellular bioactivity and infiltration.
abstract: Heparin-conjugated electrospun poly(ε-caprolactone) (PCL)/gelatin scaffolds were developed to provide controlled release of platelet-derived growth factor-BB (PDGF-BB) and allow prolonged bioactivity of this molecule. A mixture of PCL and gelatin was electrospun into three different morphologies. Next, heparin molecules were conjugated to the reactive surface of the scaffolds. This heparin-conjugated scaffold allowed the immobilization of PDGF-BB via electrostatic interaction. In vitro PDGF-BB release profiles indicated that passive physical adsorption of PDGF-BB to non-heparinized scaffolds resulted in an initial burst release of PDGF-BB within 5 days, which then leveled off. However, electrostatic interaction between PDGF-BB and the heparin-conjugated scaffolds gave rise to a sustained release of PDGF-BB over the course of 20 days without an initial burst. Moreover, PDGF-BB that was strongly bound to the heparin-conjugated scaffolds enhanced smooth muscle cell (SMC) proliferation. In addition, scaffolds composed of 3.0 μm diameter fibers that were immobilized with PDGF-BB accelerated SMC infiltration into the scaffold when compared to scaffolds composed of smaller diameter fibers or scaffolds that did not release PDGF-BB. We concluded that the combination of the large pore structure in the scaffolds and the heparin-mediated delivery of PDGF-BB provided the most effective cellular interactions through synergistic physical and chemical cues.
authors: Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
authors: Jongman
authors: J
authors: Lee
authors: James J
authors: JJ
authors: Yoo
authors: Anthony
authors: A
authors: Atala
authors: Sang Jin
authors: SJ
authors: Lee
mesh_terms: D000704:Analysis of Variance; D000077214:Becaplermin; D049109:Cell Proliferation / Q000187:drug effects; D003692:Delayed-Action Preparations; D005780:Gelatin / Q000737:chemistry; D006493:Heparin / Q000737:chemistry; D006801:Humans; D008855:Microscopy, Electron, Scanning; D032389:Myocytes, Smooth Muscle / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D011091:Polyesters / Q000737:chemistry; D020574:Proto-Oncogene Proteins c-sis / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D023822:Tissue Engineering / Q000379:methods; D054457:Tissue Scaffolds / Q000737:chemistry*
chemical_list: D003692:Delayed-Action Preparations; D011091:Polyesters; D020574:Proto-Oncogene Proteins c-sis; D000077214:Becaplermin; C016240:polycaprolactone; D005780:Gelatin; D006493:Heparin